लोड हो रहा है...
Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3‐TACC3 Fusion and Recurrent Glioblastoma
We describe a case of recurrent glioblastoma treated with anlotinib in this report. The patient was administered anlotinib 12 mg p.o. once every day (days 1–14, with a 21‐day cycle) (anlotinib clinical study NCT04004975) and oral temozolomide chemotherapy 100 mg/m(2) (days 1–7, days 15–21, 28‐day cy...
में बचाया:
| में प्रकाशित: | Oncologist |
|---|---|
| मुख्य लेखकों: | , , , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
John Wiley & Sons, Inc.
2020
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7930428/ https://ncbi.nlm.nih.gov/pubmed/32949176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13530 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|